Repligen Co. (NASDAQ:RGEN) Receives $190.25 Consensus Target Price from Brokerages

Repligen Co. (NASDAQ:RGEN) has been assigned a consensus rating of “Moderate Buy” from the ten brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $190.25.

Several analysts have weighed in on RGEN shares. Benchmark reiterated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. JPMorgan Chase & Co. upped their target price on Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a report on Wednesday, July 31st. UBS Group reduced their price objective on Repligen from $205.00 to $185.00 and set a “buy” rating for the company in a research report on Wednesday, July 31st. Stephens reaffirmed an “overweight” rating and issued a $170.00 price objective on shares of Repligen in a report on Tuesday, July 30th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $205.00 price objective on shares of Repligen in a research report on Thursday, September 26th.

Insider Activity at Repligen

In other Repligen news, Director Anthony Hunt sold 22,191 shares of the business’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the sale, the director now directly owns 139,840 shares in the company, valued at approximately $20,328,540.80. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Andra AP fonden bought a new stake in shares of Repligen during the 2nd quarter worth $25,000. International Assets Investment Management LLC purchased a new stake in shares of Repligen during the second quarter valued at $33,000. UMB Bank n.a. boosted its position in shares of Repligen by 138.3% in the 3rd quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 130 shares during the period. Lazard Asset Management LLC increased its stake in Repligen by 206.1% in the 1st quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 136 shares in the last quarter. Finally, Blue Trust Inc. raised its holdings in Repligen by 113.4% during the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock worth $36,000 after buying an additional 127 shares during the period. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Price Performance

Shares of NASDAQ RGEN opened at $138.61 on Tuesday. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $7.76 billion, a price-to-earnings ratio of -3,464.38, a price-to-earnings-growth ratio of 3.85 and a beta of 0.96. Repligen has a twelve month low of $113.50 and a twelve month high of $211.13. The business has a 50 day simple moving average of $142.04 and a 200-day simple moving average of $145.83.

About Repligen

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.